Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: Role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity

Journal of Medicinal Chemistry

Volumn 50, Issue 20, 2007, Pages 5034-5038

  La Regina, Giuseppe ^a   Coluccia, Antonio ^a   Piscitelli, Francesco ^a   Bergamini, Alberto ^d   Sinistra, Anna ^d   Cavazza, Antonella ^d   Maga, Giovanni ^c   Samuele, Alberta ^c   Zanoli, Samantha ^c   Novellino, Ettore ^b   Artico, Marino ^a   Silvestri, Romano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; INDOLE DERIVATIVE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SULFONE DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MACROPHAGE; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION;

CELL LINE; DRUG RESISTANCE, VIRAL; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; INDOLES; LYMPHOCYTES; MACROPHAGES; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES;

EID: 34948862163     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070488f     Document Type: Article

References (26)

1. Report on the Global AIDS Epidemic 2006; UNAIDS: Geneva, Switzerland, 2006.
2. Wang, L.-X. New approaches to HIV-1 inhibitor and vaccine design. Curr. Pharm. Des. 2007, 13, 127-128.
3. (a) De Clercq, E. Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. J. Med. Chem. 1995, 38, 2491-2517.
4. (b) De Clercq, E. Highlights in the development of new antiviral agents. Mini-Rev. Med. Chem. 2002, 2, 163-175.
5. (c) Williams, I. G. Enfuvirtide (Fuzeon): the first fusion inhibitor. Int. J. Clin. Pract. 2003, 57, 890-897.
6. Opar, A. New HIV drug classes on the horizon. Nat. Rev. Drug Discovery 2007, 6, 258-259.
7. Orkin, C.; Stebbing, J.; Nelson, M.; Bower, M.; Johnson, M.; Mandalia, S.; Jones, R.; Moyle, G.; Fisher, M.; Gazzard, B. A randomized study comparing a three- and four-drug HAART regimen in first-line therapy. J. Antimicrob. Chemoth. 2005, 55, 246-251.
8. Li, X.; Margolick, J. B.; Conover, C. S.; Badri, S.; Riddler, S. A.; Witt, M. D.; Jacobson, L. P. Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study. J. Acquired Immune Defic. Syndr. 2005, 38, 320-328.
9. Vandamme, A.-M.; Van Vaerenbergh, K.; De Clercq, E. Anti-human immunodeficiency virus drug combination strategies. Antiviral Chem. Chemother. 1998, 9, 187-203.
10. De Clercq, E. Non-nucleoside reverse transcriptase inhibitors (NNR-TIs): past, present, and future. Chem. Biodiversity 2004, 1, 44-64.
11. Corbett, J. W.; Rodgers, J. D. Discovery of second generation of quinazoline non-nucleoside reverse transcriptase inhibitors of HIV-1. Prog. Med. Chem. 2002, 40, 63-105.
12. Corbett, J. W.; Ko, S. S.; Rodger, J. D.; Jeffrey, S.; Bacheler, L. T.; Klabe, R. M.; Diamond, S.; Lai, C.-M.; Rabel, S. R.; Saye, J. A.; Adams, S. P.; Trainor, G. L.; Anderson, P. S.; Erickson-Viitanen, S. K. Expanded-spectrum non-nucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 1999, 43, 2893-2897.
13. Artico, M.; Silvestri, R.; Pagnozzi, E.; Stefancich, G.; Massa, S.; Loi, A. G.; Putzolu, M.; Corrias, S.; Spiga, M. G.; La Colla, P. Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs): a novel class of non-nucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem. 1996, 4, 837-50.
14. (a) Artico, M.; Silvestri, R.; Pagnozzi, E.; Bruno, B.; Novellino, E.; Greco, G.; Massa, S.; Ettorre, A.; Loi, A. G.; Scintu, F.; La Colla, P. Structure-based design, synthesis, and biological evaluation of novel pyrrolyl aryl sulfones: HIV-1 non-nucleoside reverse transcriptase inhibitors active at nanomolar concentrations. J. Med. Chem. 2000, 43, 1886-1891.
15. (b) Artico, M.; Silvestri, R.; Massa, S.; Loi, A. G.; Corrias, S.; Piras, G.; La Colla, P. 2-Sulfonyl-4-chloroanilino moiety: a potent pharmacophore for the anti-human immunodeficiency virus type 1 activity of pyrrolyl aryl sulfones. J. Med. Chem. 1996, 39, 522-530.
16. (a) Silvestri, R.; De Martino, G.; La Regina, G.; Artico, M.; Massa, S.; Vargiu, L.; Mura, M.; Loi, A. G.; Marceddu, T.; La Colla, P. Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies. J. Med. Chem, 2003, 46, 2482-2493.
17. (b) La Colla, P.; Artico, M.; Sommadossi, J. P. Use of phenylindoles for the treatment of HIV. PCT Int. Appl. WO 2002083126, 2002.
18. (a) Silvestri, R.; Artico, M.; De Martino, G.; La Regina, G.; Loddo, R.; La Colla, M.; La Colla, P. Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild-type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations. J. Med. Chem. 2004, 47, 3892-3896.
19. (b) Ragno, R.; Artico, M.; De Martino, G.; La Regina, G.; Coluccia, A.; Di Pasquali, A.; Silvestri, R. Docking and 3-D QSAR studies on indolyl aryl sulfones (IASs). Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2- hydroxyethyl)carboxamide and N-(2-hydroxyethyl)-carbohydrazide derivatives. J. Med. Chem. 2005, 48, 213-223.
20. (c) Ragno, R.; Coluccia, A.; La Regina, G.; De Martino, G.; Piscitelli, F.; Lavecchia, A.; Novellino, E.; Bergamini, A.; Ciaprini, C.; Sinistro, A.; Maga, G.; Crespan, E.; Artico, M.; Silvestri, R. Design, molecular modeling, synthesis and anti-HIV-1 activity of new indolyl aryl sulfones. Novel derivatives of the indole-2-carboxamide. J. Med. Chem. 2006, 49, 3172-3184.
21. (d) De Martino, G.; La Regina, G.; Ragno, R.; Coluccia, A.; Bergamini, A.; Ciaprini, C.; Sinistro, A.; Maga, G.; Crespan, E.; Artico, M.; Silvestri, R. Indolyl aryl sulfones (IASs) as HIV-1 non-nucleoside reverse transcriptase inhibitors: synthesis, biological evaluation and binding mode studies of new derivatives at indole-2-carboxamide. Antiviral Chem. Chemother. 2006, 57, 59-77.
22. Robinson, B. The Fischer Indole Synthesis; J. Wiley and Sons: Chichester, U.K., 1982.
23. Silvestri, R.; Artico, M.; La Regina, G.; De Martino, G. Synthetic approaches to difluoroindolecarboxylic acid ethyl esters. ARKIVOC 2004, 5, 26-31.
24. Heath-Brown, B.; Philpott, P. G. The indole series. III. The Japp-Klingemann reaction. J. Chem. Soc. 1965, 7185-7193.
25. Silvestri, R.; De Martino, G.; Sbardella, G. A simplified synthesis of ethyl 5-chloro-6-fluoro-1H-indole-2-carboxylate and ethyl 5-chloro-4-fluoro-1H-indole-2-carboxylate. Org. Prep. Proced. Int. 2002, 34, 507-510.
26. +-ATPase of osteoclasts with bone antiresorptive activity. J. Med. Chem. 1998, 41, 1568-1573.